Oneness Biotech Co., Ltd. receives an Indonesian
patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND
HEALING" on Fespixon cream (Research code: ON101).
Date of events
2022/03/18
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event:2022/03/18
2.Company name:ONENESS BIOTECH CO., LTD.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:The Company has been informed by the patent agency
that an Indonesian patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND
HEALING" has been granted on the new drug Fespixon cream (Research code:
ON101) under the patent number IDP000079390.
6.Countermeasures:None
7.Any other matters that need to be specified:
(1)The new drug, Fespixon cream has been granted many international patents.
The development of new drugs is lengthy so many new drugs are faced with
expiring patent protection shortly after their market approval, which
results in loss of market exclusivity. The Company has filed a new patent
for the topical formulation of Fespixon cream with innovative and
efficacious scientific data and has been granted such patent in the U.S.,
the largest market in February 2021, and subsequently also granted in
Russia, Mexico, Taiwan, Korea and Indonesia.
(2)The patent of the topical formulation of Fespixon new drug has been filed
in major countries or regions of the global market. The granted patent
term remains valid till 2037-2038. Extension of the patent term can be
applied for up to 5 years after the product is approved to be marketed.
(3)During the term of the granted patent, Fespixon cream will be protected
against any generic competition.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Oneness Biotech Co Ltd. published this content on 18 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 March 2022 09:20:06 UTC.
ONENESS BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the research, development, production and sales of health products. The Company's main products include health supplies, health food and healthy food. The Company is also involved in the development of new drugs for the treatment of wound healing in chronic diabetic foot ulcers, as well as the development of new anticancer drugs. The Company distributes its products in domestic market.
ONENESS BIOTECH CO., LTD. 
